Lv4
450 积分 2023-03-16 加入
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial
2天前
已完结
Autoimmune haemolytic anaemias
3天前
已完结
Canonical and non-canonical roles of complement in atherosclerosis
3天前
已完结
Complosome — the intracellular complement system
3天前
已完结
A guide to complement biology, pathology and therapeutic opportunity
3天前
已完结
Complement therapeutics are coming of age in rheumatology
3天前
已完结
Canonical and non-canonical roles of complement in atherosclerosis
3天前
已完结
Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition
3天前
已完结
221 SYNERGY-1: A Phase 1, first-in-human, randomized, double-blind, placebo-controlled safety, tolerability, immunogenicity, PK and PD study of KP104 in escalating single and multiple doses
3天前
求助中
In vivo CAR engineering for immunotherapy
23天前
已完结
皖公网安备34019202002308
